The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome

Phase 4

Recruiting

• Conditions: Velocardiofacial Syndrome; Williams Syndrome; Fragile X Syndrome
• Interventions: Drug: methylphenidate, fluoxetin, risperidone

• Registration Number: NCT00768820
• Lead Sponsor: The Chaim Sheba Medical Center

Brief Summary

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Detailed Description

Not available

Study Timeline

• Study Start: 2001-05
• Study First Submitted: 2008-10-07
• Study First Submitted QC: 2008-10-07
• Study First Posted: 2008-10-08
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-06
• Last Update Posted: 2024-05-07
• Primary Completion: 2024-08
• Study Completion: 2024-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• chromosomal deletion proven by FISH examination

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	methylphenidate, fluoxetin, risperidone	-

Primary Outcome Measures

Name	Time	Method
Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments	2 years

Trial Locations

Locations (1)

Schneider Children's Mediac Center of Israel; 🇮🇱 Petach-Tikva, Israel